Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 179 articles: HTML format

Single Articles

October 2026
1. ZHAO C, Kawaguchi ES, Maskarinec G, Conti DV, et al
   Lifestyle and genetic risk factors for postmenopausal breast cancer in the multiethnic cohort.
   J Natl Cancer Inst. 2026 Oct 15:djag394. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. AHMED S, Seror R, Mariette X, Maclin BJ, et al
   Associations between breast cancer and rheumatoid arthritis among older-age women in the United States.
   J Natl Cancer Inst. 2026 Oct 13:djag387. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. BODELON C, McCullough LE, York C, Shams-White MM, et al
   Alignment with lifestyle recommendations and physical health in breast cancer survivors and women without cancer.
   J Natl Cancer Inst. 2026 Oct 13:djag388. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. ZHANG X, Shi J
   RE: Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study.
   J Natl Cancer Inst. 2026 Oct 12:djag378. doi: 10.1093.
   PubMed    
   
   
   
5. RAGHAVENDRA AS, Kotecki N, Jennings K, Amato O, et al
   A validated clinical calculator of a brain metastasis risk (BrMR) prediction model in stage I-III breast cancer patients.
   J Natl Cancer Inst. 2026 Oct 8:djag377. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. VALENZA C, Zheng Y, Leone JP, Trapani D, et al
   21-Gene recurrence score assay in pN2-3 Early-Stage breast cancer: a national cancer database study.
   J Natl Cancer Inst. 2026 Oct 6:djag374. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. JOHN EM, Kwan ML, Koo J, Von Behren J, et al
   Obesity and survival of Asian American and White women with breast cancer.
   J Natl Cancer Inst. 2026 Oct 1:djag348. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. MURPHY PK, Sellers ME, Cronin KA
   Stat Bite: Breast cancer subtype incidence rates in women under 50 from 2019 to 2023.
   J Natl Cancer Inst. 2026;118:1987.
   PubMed    
   
   
   
9. ABDOU Y, Hoag J, Barlow WE, Albain KS, et al
   Recurrence Score gene group components and outcomes in the RxPONDER trial (SWOG S1007).
   J Natl Cancer Inst. 2026;118:1953-1962.
   PubMed     Abstract available
   
   
   
10. HALL P, Hammarstrom M, Bergqvist J, Czene K, et al
    Endoxifen for mammographic density reduction-results from the KARISMA endoxifen trial.
    J Natl Cancer Inst. 2026;118:1899-1906.
    PubMed     Abstract available
    
    
    
11. PURJA S, Kim E
    Adaptive design increased success but does not significantly accelerate confirmatory oncology trials.
    J Natl Cancer Inst. 2026;118:1888-1898.
    PubMed     Abstract available
    
    
    September 2026
12. VO JB, Mitra PR, Corley ME, Shiels MS, et al
    Trends in U.S. breast cancer mortality by estrogen receptor status.
    J Natl Cancer Inst. 2026 Sep 30:djag347. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. HARTMAN SJ, Shao LY, Zablocki RW, Natarajan L, et al
    Effectiveness of an exercise intervention on cognition in breast cancer survivors: a randomized controlled trial.
    J Natl Cancer Inst. 2026 Sep 30:djag295. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. CARLIN D, Ott O, Sears DD, Ahles T, et al
    Exercise slows biological aging in breast cancer survivors: secondary analysis of a randomized trial.
    J Natl Cancer Inst. 2026 Sep 30:djag296. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. RUIZ DE AZUA G, Licaj I, Ntobeng K, Havas J, et al
    Explaining educational differences in return to work after early breast cancer: a mediation analysis.
    J Natl Cancer Inst. 2026 Sep 29:djag350. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. CESPEDES FELICIANO EM, Fuller SE, Nugent JR, Cao A, et al
    Lifestyle and chemotherapy shape functional aging trajectories in older breast cancer survivors and matched comparators.
    J Natl Cancer Inst. 2026 Sep 23:djag292. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. PIMENTEL-PARRA GA, Escalada-Hernandez P, San Martin-Rodriguez L, Garcia-Vivar C, et al
    Effectiveness of an eHealth intervention to improve quality of life in long-term breast cancer survivors: a 9-month randomized controlled trial.
    J Natl Cancer Inst. 2026 Sep 16:djag328. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. NJOR SH, Pedersen CU, Lynge E, Smith RA, et al
    Breast cancer overdiagnosis in mammography trials-separating signal from noise: a meta-analysis.
    J Natl Cancer Inst. 2026 Sep 14:djag302. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. SERRANO D, Rizzo R, Johansson H, Macis D, et al
    SHBG as a breast cancer risk biomarker in premenopausal women? Results from an individual patient's pooled analysis and a meta-analysis.
    J Natl Cancer Inst. 2026 Sep 11:djag318. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. NASH S, Hammarstrom M, Thorngen JO, Winqvist O, et al
    Endocrine Biomarker Changes in a Randomised Low-Dose Tamoxifen Trial for Breast Cancer Prevention.
    J Natl Cancer Inst. 2026 Sep 10:djag321. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. COSTA DE ALMEIDA LF, Cappellaro AP, Noronha MM, Diniz da Conceicao L, et al
    Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.
    J Natl Cancer Inst. 2026 Sep 10:djag324. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. 
    Correction: TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
    J Natl Cancer Inst. 2026 Sep 10:djag277. doi: 10.1093.
    PubMed    
    
    
    
23. SRINIVASAN A, Wang J, Matt G, Mills LJ, et al
    Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.
    J Natl Cancer Inst. 2026 Sep 9:djag306. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2026
24. PATEL R, Sparano JA
    Racial disparities in breast cancer: looking beyond the recurrence score.
    J Natl Cancer Inst. 2026 Aug 28:djag253. doi: 10.1093.
    PubMed    
    
    
    
25. ZAHWE M, Znaor A, Bardot A, Joshi S, et al
    Benchmarking female breast cancer survival in africa, Central and South america, and asia (SURVCAN-3).
    J Natl Cancer Inst. 2026 Aug 22:djag294. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. MASSA D, Chiappe E, Delucchi V, Girardi F, et al
    Endocrine therapy in early-stage estrogen Receptor-Low breast cancer: a systematic review and Meta-Analysis.
    J Natl Cancer Inst. 2026 Aug 18:djag281. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. LAPIDARI P, Lustberg M, Havas J, Pagliuca M, et al
    Development and validation of a predictive model of aromatase inhibitor-induced arthralgia among patients with early breast cancer.
    J Natl Cancer Inst. 2026 Aug 18:djag280. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. ARECCO L, Blondeaux E, Bruzzone M, de Azambuja E, et al
    Refining risk stratification of patients with early breast cancer eligible for adjuvant abemaciclib or ribociclib.
    J Natl Cancer Inst. 2026 Aug 14:djag264. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. AGOSTINETTO E, Gentile G, Samy F, Di Cosimo S, et al
    The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial.
    J Natl Cancer Inst. 2026;118:1504-1513.
    PubMed     Abstract available
    
    
    July 2026
30. JI J, Sun CL, Dale W, Cohen HJ, et al
    Early discontinuation of chemotherapy in older adults with early breast cancer: results from the prospective multicenter HOPE study.
    J Natl Cancer Inst. 2026 Jul 30:djag250. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. PATEL R, Kwa M, Klein P, Fasano J, et al
    A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE).
    J Natl Cancer Inst. 2026 Jul 30:djag256. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. ROUSSEL-SIMONIN C, Rassy E
    The unfinished story of pregnancy-associated breast cancer.
    J Natl Cancer Inst. 2026 Jul 25:djag191. doi: 10.1093.
    PubMed    
    
    
    
33. PARK B, Yoon J, Jeon S, Nguyen THT, et al
    Association between smoking habits and breast density, changes in breast density, and breast cancer in Asian women.
    J Natl Cancer Inst. 2026 Jul 21:djag231. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. TARANTINO P, Curigliano G, Hamilton E, Kim J, et al
    Recurrence risk in HR-positive/HER2-negative early breast cancer: real-world US electronic health records study.
    J Natl Cancer Inst. 2026 Jul 11:djag201. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. BUONAIUTO R, Pagliuca M, Longobardi A, Cataldo ML, et al
    Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis.
    J Natl Cancer Inst. 2026 Jul 10:djag220. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. SHAH Z, Lei L, Thakur R, Buradkar A, et al
    Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates.
    J Natl Cancer Inst. 2026 Jul 7:djag223. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. LEE CI, Lowry KP, Elmore JG
    Breast cancer risk prediction with artificial intelligence: promise, calibration, and clinical readiness.
    J Natl Cancer Inst. 2026 Jul 6:djag121. doi: 10.1093.
    PubMed    
    
    
    
38. SHEN P, Chen X, Wang C, Xu F, et al
    RE?Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.
    J Natl Cancer Inst. 2026 Jul 3:djag187. doi: 10.1093.
    PubMed    
    
    
    
39. MINAMI CA, Jager LR, Lorentzen EH, Shadyab AH, et al
    Worsening frailty and declining quality of life in older survivors of non-metastatic breast cancer.
    J Natl Cancer Inst. 2026 Jul 3:djag218. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. CASAGRANDE CC, Deardorff RL, Zhai W, Small BJ, et al
    Longitudinal effects of comorbidities on brain structure and cognition in older breast cancer survivors.
    J Natl Cancer Inst. 2026 Jul 3:djag219. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. CREW KD, Anderson GL, Arnold KB, Dzingle S, et al
    Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.
    J Natl Cancer Inst. 2026 Jul 2:djag216. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2026
42. CASTRO-ESPIN C, His M, Fournier A, Biessy C, et al
    Pre-diagnosis thyroid biomarkers and breast cancer survival: evidence from a European prospective cohort study.
    J Natl Cancer Inst. 2026 Jun 25:djag195. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. ARASU VA, Gadgil T, Rothstein JH, Alexeeff SE, et al
    Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research Bank.
    J Natl Cancer Inst. 2026 Jun 23:djag154. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. WANG X, Xu X, Li Y
    RE: Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.
    J Natl Cancer Inst. 2026 Jun 12:djag188. doi: 10.1093.
    PubMed    
    
    
    
45. PILEHVARI A, Anderson RT, Shelby R, Kimmick G, et al
    Adjuvant chemotherapy for breast cancer: are all dose reductions inappropriate?
    J Natl Cancer Inst. 2026 Jun 9:djag113. doi: 10.1093.
    PubMed    
    
    
    
46. VAN DUIJNE HM, Berentzen NE, Vermeulen RC, Vlaanderen JJ, et al
    Change in body mass index and physical activity and postmenopausal breast cancer risk in a cohort of Dutch nurses.
    J Natl Cancer Inst. 2026 Jun 5:djag177. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2026
47. RUSSO RG, Hernan MA, Dahabreh IJ, Rimm EB, et al
    Statins and risk of cardiovascular disease: Emulating a primary prevention trial in breast cancer survivors.
    J Natl Cancer Inst. 2026 May 29:djag158. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. YU S, Wang X, Ge H
    RE: Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.
    J Natl Cancer Inst. 2026 May 19:djag149. doi: 10.1093.
    PubMed    
    
    
    
49. NADER-MARTA G, Zheng Y, Rosenberg SM, Dibble KE, et al
    Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer.
    J Natl Cancer Inst. 2026 May 18:djag152. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. SHI H, Chen S, Tang Y
    RE: Tamoxifen therapy benefit in luminal a and B breast cancer with 20-year follow-up.
    J Natl Cancer Inst. 2026 May 3:djag131. doi: 10.1093.
    PubMed    
    
    
    
51. LI R, Liu Z, Zhang S, Wu X, et al
    RE: Tamoxifen therapy benefit in luminal a and B breast cancer with 20-year follow-up.
    J Natl Cancer Inst. 2026 May 3:djag132. doi: 10.1093.
    PubMed    
    
    
    April 2026
52. O'CONNELL CP, Burns KF, Hong HG, Kahle L, et al
    Title: Ultra-processed food intake and postmenopausal breast cancer risk in the NIH-AARP diet and health study.
    J Natl Cancer Inst. 2026 Apr 21:djag124. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. SPOOR J, Mureau MAM, de Jong D, Tissier RLM, et al
    Risk of autoimmune and rheumatic diseases in breast cancer patients with silicone breast implants.
    J Natl Cancer Inst. 2026 Apr 19:djag115. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. LAMMERS EM, Zijlstra JM, Schaapveld M, Haagsma JA, et al
    The impact of survivorship care on burden of disease among Hodgkin lymphoma survivors.
    J Natl Cancer Inst. 2026 Apr 11:djag080. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. JAYASEKERA J, Hooshmand S, Strassle PD, Schneider J, et al
    Breast cancer mortality by age and race and/or ethnicity across counties in the United States, 2000-2019.
    J Natl Cancer Inst. 2026 Apr 3:djag103. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. NG DQ, Heshmatipour M, Trudeau J, Sridhar A, et al
    Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.
    J Natl Cancer Inst. 2026 Apr 2:djag096. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2026
57. KAUL M, Scott CG, Wadzinske A, Banerjee I, et al
    Performance of clinical breast cancer risk prediction models versus a mammography-based artificial intelligence risk model.
    J Natl Cancer Inst. 2026 Mar 26:djag083. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. KWAN ML, D'Addario L, Lee C, Roh JM, et al
    Differences in breast cancer survival across Asian American ethnicities compared with non-Latina White females in Kaiser Permanente Northern California.
    J Natl Cancer Inst. 2026 Mar 26:djag062. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. ABOUMRAD M, Joshu C, Jackson J, Visvanathan K, et al
    Antidepressant adherence and breast cancer recurrence risk in women with major depressive disorder: a retrospective cohort.
    J Natl Cancer Inst. 2026 Mar 21:djag076. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. YADAV S, Reid S, Yilma B, Fragkogianni S, et al
    Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes.
    J Natl Cancer Inst. 2026 Mar 14:djag070. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. SAMPATHKUMAR Y, Zakaria Z, O'Connell K, Bhimani J, et al
    Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.
    J Natl Cancer Inst. 2026 Mar 4:djag063. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2026
62. WOOLPERT KM, Kjaersgaard A, Schapira L, Toft Sorensen H, et al
    Opioid use after breast cancer in Denmark: a nationwide study of social and clinical factors.
    J Natl Cancer Inst. 2026 Feb 25:djag052. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. DANIELSSON O, Dar H, Nordenskjold A, Perez-Tenorio G, et al
    Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.
    J Natl Cancer Inst. 2026 Feb 19:djag049. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. TICKLE A, Offman J, North B, Jorgensen SF, et al
    Improved stage-specific survival in screen-detected breast cancer in Denmark: a cohort study.
    J Natl Cancer Inst. 2026 Feb 19:djaf377. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. KORIC A, Bennett DL, Boulos F, Colditz GA, et al
    Subsequent breast cancer risk after benign biopsy in racially diverse women: Siteman Cancer Center.
    J Natl Cancer Inst. 2026 Feb 16:djag048. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. RICHMAN IB, Lindsay ME, Long JB, Epstein E, et al
    Diagnostic yield of surveillance mammography among older women.
    J Natl Cancer Inst. 2026;118:223-230.
    PubMed     Abstract available
    
    
    
67. TUNG N, Hollis RL, Viale G, Tweed C, et al
    Questions and answers on PARP inhibitor use in somatic BRCA-mutated breast cancers.
    J Natl Cancer Inst. 2026;118:205-213.
    PubMed     Abstract available
    
    
    January 2026
68. PIMENTEL-PARRA GA, Soto-Ruiz N, Escalada-Hernandez P, San Martin-Rodriguez L, et al
    EHealth intervention for quality of life in long-term breast cancer survivors: Randomized controlled trial.
    J Natl Cancer Inst. 2026 Jan 24:djag020. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. SHERMAN ME, Etievant L, Vierkant RA, Winham SJ, et al
    Postpartum breast cancer: evidence for a distinct phenotype.
    J Natl Cancer Inst. 2026 Jan 9:djag003. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. LEHRER S
    Re: Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
    J Natl Cancer Inst. 2026 Jan 8:djaf339. doi: 10.1093.
    PubMed    
    
    
    
71. LOWRY KP, Jeong HE, Kim KH, Hughes KS, et al
    Current state of mammography-based artificial intelligence for future breast cancer risk prediction: a systematic review.
    J Natl Cancer Inst. 2026 Jan 7:djag002. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. IM C, Hasan H, Srinivasan A, Stene E, et al
    Breast cancer recurrence and mortality among survivors of childhood cancer.
    J Natl Cancer Inst. 2026 Jan 7:djag005. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. WESTVOLD SJ, Long JB, Fan J, Kc M, et al
    Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer.
    J Natl Cancer Inst. 2026;118:130-140.
    PubMed     Abstract available
    
    
    
74. BAILEY JT, Chang CJ, Gaston SA, Jackson CL, et al
    Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.
    J Natl Cancer Inst. 2026;118:94-101.
    PubMed     Abstract available
    
    
    December 2025
75. SHAO L, Wang Y, Shieh Y, Tamimi RM, et al
    Second primary cancer in breast cancer survivors by race/ethnicity and asian subgroups: a descriptive epidemiologic study.
    J Natl Cancer Inst. 2025 Dec 23:djaf372. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. SEMPRINI J
    RE: Ambient air pollution and mortality in older patients with breast cancer.
    J Natl Cancer Inst. 2025 Dec 17:djaf369. doi: 10.1093.
    PubMed    
    
    
    
77. KOTSOPOULOS J, Seca M, Gronwald J, Huzarski T, et al
    Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.
    J Natl Cancer Inst. 2025 Dec 17:djaf363. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. JOURQUIN J, Dickerson JC, Marks EG, Epps J, et al
    Susan G. Komen's ShareForCures(R): a patient-engaged, nationwide breast cancer research registry.
    J Natl Cancer Inst. 2025 Dec 13:djaf353. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. MATTICK LJ, Li CS, Lin PJ, Peppone LJ, et al
    Walking dose associated with lower cancer-related fatigue among patients with breast cancer.
    J Natl Cancer Inst. 2025 Dec 13:djaf360. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. HU X, Cai C, Arshad S, Anderson JN, et al
    Potential role of perceived discrimination and sociodemographics on racial disparities in breast cancer symptom burden.
    J Natl Cancer Inst. 2025 Dec 9:djaf301. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. SHUMWAY DA, Corbin KS, Shiraishi S, Farah MH, et al
    Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation.
    J Natl Cancer Inst. 2025 Dec 6:djaf346. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. NASSAR AH, Bou Farhat E, Abushukair H, Alchoueriy M, et al
    Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer.
    J Natl Cancer Inst. 2025 Dec 4:djaf344. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. HAZELWOOD E, Goudswaard LJ, Lee MA, Vabistsevits M, et al
    Adiposity distribution and risks of 12 obesity-related cancers: a Mendelian randomization analysis.
    J Natl Cancer Inst. 2025;117:2621-2642.
    PubMed     Abstract available
    
    
    November 2025
84. CHOI E, Zhai W, Ahn J, Ahles TA, et al
    Neighborhood deprivation on increasing deficit accumulation in older breast cancer survivors and non-cancer controls.
    J Natl Cancer Inst. 2025 Nov 22:djaf337. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. WORTELBOER N, Kent S, Blommestein HM, van Ommen-Nijhof A, et al
    Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.
    J Natl Cancer Inst. 2025 Nov 21:djaf334. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. ORLANDI A
    RE: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
    J Natl Cancer Inst. 2025 Nov 5:djaf319. doi: 10.1093.
    PubMed    
    
    
    
87. AIELLO BOWLES EJ, O'Connell K, Bhimani J, Gallagher GB, et al
    Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer.
    J Natl Cancer Inst. 2025 Nov 3:djaf314. doi: 10.1093.
    PubMed     Abstract available
    
    
    
88. LIU Q, Wiese D, Pinheiro PS, Bispo JB, et al
    Association between racialized economic segregation and stage at diagnosis for 3 screenable cancers in New York City.
    J Natl Cancer Inst. 2025;117:2259-2271.
    PubMed     Abstract available
    
    
    
89. VO JB, Brown DW, Buller ID, Shing JZ, et al
    Associations of self-identified race and ethnicity and genetic ancestry with mortality among cancer survivors.
    J Natl Cancer Inst. 2025;117:2382-2387.
    PubMed     Abstract available
    
    
    October 2025
90. 
    Correction to: Discovering plasma proteins associated with breast cancer incidence in postmenopausal women in the Atherosclerosis Risk in Communities study.
    J Natl Cancer Inst. 2025 Oct 17:djaf284. doi: 10.1093.
    PubMed    
    
    
    
91. OTTAVIANI D, Ola M, Allotta A, Maati Chaibi Y, et al
    Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
    J Natl Cancer Inst. 2025 Oct 15:djaf295. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. NADER-MARTA G, Chu X, Mukhopadhyay S, Abramson VG, et al
    Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
    J Natl Cancer Inst. 2025 Oct 11:djaf289. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. NGUYEN THT, Jeon S, Yoon J, Park B, et al
    Independent associations between obesity, glucose metabolism, and breast cancer risk through unrelated pathways.
    J Natl Cancer Inst. 2025 Oct 8:djaf287. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2025
94. SYMONDS LK, Davidson NE
    RecOVARY? Using anti-Mullerian hormone to predict ovarian function after anti-HER2 therapy for early breast cancer.
    J Natl Cancer Inst. 2025 Sep 26:djaf247. doi: 10.1093.
    PubMed    
    
    
    
95. SEEWALDT VL, Schedin PJ
    Breastfeeding after breast cancer: a need for further mechanistic study.
    J Natl Cancer Inst. 2025 Sep 18:djaf240. doi: 10.1093.
    PubMed    
    
    
    
96. IRAJIZAD E, Hanash S
    Breast cancer risk assessment: current challenges and the emerging role of blood-based protein biomarkers.
    J Natl Cancer Inst. 2025 Sep 3:djaf215. doi: 10.1093.
    PubMed    
    
    
    
97. PRESTI D, Di Meglio A, Havas J, Pagliuca M, et al
    Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort.
    J Natl Cancer Inst. 2025 Sep 3:djaf256. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. SAHIN TK, Guven DC, Aksoy S
    RE: Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
    J Natl Cancer Inst. 2025 Sep 3:djaf254. doi: 10.1093.
    PubMed    
    
    
    August 2025
99. CARBONE A, Oliva M, Puntoni M, Guerrieri-Gonzaga A, et al
    Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer.
    J Natl Cancer Inst. 2025 Aug 28:djaf250. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. TARANTINO P, Lee D, Foldi J, Soulos PR, et al
     Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
     J Natl Cancer Inst. 2025 Aug 14:djaf220. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. LAMBERTINI M, Allegranza D, Laubender RP, Harbeck N, et al
     Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
     J Natl Cancer Inst. 2025 Aug 12:djaf198. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. MO T, Partridge A, Joffe M, Cubasch H, et al
     Survival deficits in young women with breast cancer in Sub-Saharan africa: the ABC-DO cohort.
     J Natl Cancer Inst. 2025 Aug 7:djaf213. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. WEI Y, Castro E, Yin K, Zhang M, et al
     Ambient air pollution and mortality in older breast cancer patients.
     J Natl Cancer Inst. 2025 Aug 5:djaf217. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. SPOOR J, Mureau MAM, Tissier RLM, Hommes J, et al
     Breast implant illness after reconstruction with silicone breast implants.
     J Natl Cancer Inst. 2025;117:1717-1728.
     PubMed     Abstract available
     
     
     
105. YU TT, Hoyt AC, Joines MM, Fischer CP, et al
     Mammographic classification of interval breast cancers and artificial intelligence performance.
     J Natl Cancer Inst. 2025;117:1627-1638.
     PubMed     Abstract available
     
     
     July 2025
106. ZHU T, Bu J, Zhu X
     RE: Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
     J Natl Cancer Inst. 2025 Jul 23:djaf187. doi: 10.1093.
     PubMed    
     
     
     
107. WATT GP, Reiner AS, Shu X, Malone KE, et al
     Polygenic risk of coronary artery disease for long-term survivors of breast cancer.
     J Natl Cancer Inst. 2025 Jul 16:djaf189. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. BOTTERI E, Hjorth S, Conforti F, Bagnardi V, et al
     Aprepitant use during chemotherapy and association with survival in women with early breast cancer.
     J Natl Cancer Inst. 2025 Jul 14:djaf178. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. SYLEOUNI ME, Joshu CE, Coresh J, Gunter MJ, et al
     Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC.
     J Natl Cancer Inst. 2025 Jul 7:djaf170. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. BLONDEAUX E, Delucchi V, Mariamidze E, Bernstein-Molho R, et al
     Breastfeeding after breast cancer in young BRCA carriers.
     J Natl Cancer Inst. 2025 Jul 7:djaf177. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. STECKLEIN SR, Martin M, Villacampa G, Del Monte-Millan M, et al
     Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.
     J Natl Cancer Inst. 2025 Jul 2:djaf162. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. FAN Q, Dong W, Schafer EJ, Wagle NS, et al
     Changes in time-to-treatment initiation for breast, non-small cell lung, colon, or rectal cancers throughout the COVID-19 pandemic in the United States.
     J Natl Cancer Inst. 2025;117:1506-1511.
     PubMed     Abstract available
     
     
     June 2025
113. ARECCO L, Blondeaux E, Bruzzone M, Arpino G, et al
     Prognostic implications of risk definitions from the monarchE and NATALEE trials.
     J Natl Cancer Inst. 2025;117:1198-1208.
     PubMed     Abstract available
     
     
     May 2025
114. ABUBAKAR M, Duggan MA, Fan S, Pfeiffer RM, et al
     Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes.
     J Natl Cancer Inst. 2025 May 14:djaf070. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. LI D, Liu Y, Duan Q, Chen X, et al
     RE: Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
     J Natl Cancer Inst. 2025 May 7:djaf115. doi: 10.1093.
     PubMed    
     
     
     
116. TUESLEY KM, Spilsbury K, Pearson SA, Donovan P, et al
     Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.
     J Natl Cancer Inst. 2025;117:1046-1055.
     PubMed     Abstract available
     
     
     
117. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
     Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
     J Natl Cancer Inst. 2025;117:1018-1026.
     PubMed     Abstract available
     
     
     
118. BUQUE A, Bloy N, Petroni G, Jimenez-Cortegana C, et al
     Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor-positive mammary carcinogenesis.
     J Natl Cancer Inst. 2025;117:934-947.
     PubMed     Abstract available
     
     
     April 2025
119. ZHANG J, Zhang L, Liu Z, Jia Y, et al
     RE: Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.
     J Natl Cancer Inst. 2025 Apr 9:djaf093. doi: 10.1093.
     PubMed    
     
     
     
120. LOPEZ-FERNANDEZ A, Duran-Lozano L, Villacampa G, Pardo M, et al
     A randomized study of 2 risk assessment models for individualized breast cancer risk estimation.
     J Natl Cancer Inst. 2025 Apr 1:djaf067. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. BARGON CA, Mink van der Molen DR, Young-Afat DA, Batenburg MCT, et al
     Clinical and patient-reported outcomes after oncoplastic vs conventional breast-conserving surgery-a longitudinal, multicenter cohort study.
     J Natl Cancer Inst. 2025;117:781-789.
     PubMed     Abstract available
     
     
     
122. LI S, Madanat-Harjuoja L, Leslie G, Barnes DR, et al
     Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers.
     J Natl Cancer Inst. 2025;117:728-736.
     PubMed     Abstract available
     
     
     
123. STROOT IAS, Bart J, Hollema H, Wagner MM, et al
     High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.
     J Natl Cancer Inst. 2025;117:719-727.
     PubMed     Abstract available
     
     
     
124. HAMMARSTROM M, Gabrielson M, Bergqvist J, Lundholm C, et al
     Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial.
     J Natl Cancer Inst. 2025;117:629-636.
     PubMed     Abstract available
     
     
     March 2025
125. KURIAN AW, Furgal AKC, Radhakrishnan A, Veenstra CM, et al
     Extended endocrine therapy use and decision making after breast cancer diagnosis.
     J Natl Cancer Inst. 2025 Mar 31:djaf076. doi: 10.1093.
     PubMed     Abstract available
     
     
     
126. SAMMONS SL, Sanglier T, Leone JP, Erick TK, et al
     Prevalence by therapy line and incidence of breast cancer brain metastases in 18,075 patients.
     J Natl Cancer Inst. 2025 Mar 31:djaf048. doi: 10.1093.
     PubMed     Abstract available
     
     
     
127. LYNCE F, Niman SM, Kai M, Ma SR, et al
     Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic Score.
     J Natl Cancer Inst. 2025 Mar 31:djaf088. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. BETTARIGA F, Taaffe DR, Borsati A, Avancini A, et al
     Effects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis.
     J Natl Cancer Inst. 2025 Mar 20:djaf062. doi: 10.1093.
     PubMed     Abstract available
     
     
     
129. HUANG Y, Kwan ML, Heckbert SR, Smith NL, et al
     Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.
     J Natl Cancer Inst. 2025 Mar 11:djaf063. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2025
130. HU P, Prorok PC, Katki HA
     Design of randomized controlled trials to estimate cancer-mortality reductions from multicancer detection screening.
     J Natl Cancer Inst. 2025;117:303-311.
     PubMed     Abstract available
     
     
     January 2025
131. MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al
     NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
     J Natl Cancer Inst. 2025;117:120-133.
     PubMed     Abstract available
     
     
     
132. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
     Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
     J Natl Cancer Inst. 2025;117:188-197.
     PubMed     Abstract available
     
     
     
133. GANZ PA, Cecchini RS, White JR, Vicini FA, et al
     Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery.
     J Natl Cancer Inst. 2025;117:103-111.
     PubMed     Abstract available
     
     
     December 2024
134. ZHANG Y, Lv P
     RE: Genetic risk, health-associated lifestyle, and risk of early-onset total cancer and breast cancer.
     J Natl Cancer Inst. 2024 Dec 19:djae322. doi: 10.1093.
     PubMed    
     
     
     
135. LOLAS-HAMAMEH S, Lieberman S, Sarahneh A, Walsh T, et al
     TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers.
     J Natl Cancer Inst. 2024 Dec 14:djae334. doi: 10.1093.
     PubMed     Abstract available
     
     
     
136. PETITJEAN C, Wilcox N, Ficorella L, Dennis J, et al
     Evaluating the performance of the BOADICEA model in predicting 10-year breast cancer risks in UK Biobank.
     J Natl Cancer Inst. 2024 Dec 12:djae335. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. ABDOU Y, Barlow WE, Gralow JR, Meric-Bernstam F, et al
     Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
     J Natl Cancer Inst. 2024 Dec 5:djae314. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. PALMER S, Valachis A, Lindman H, Smith DR, et al
     Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancer.
     J Natl Cancer Inst. 2024 Dec 4:djae315. doi: 10.1093.
     PubMed     Abstract available
     
     
     
139. JOHANSSON A, Dar H, Nordenskjold A, Perez-Tenorio G, et al
     Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
     J Natl Cancer Inst. 2024 Dec 4:djae268. doi: 10.1093.
     PubMed     Abstract available
     
     
     
140. SERRANO D, Johansson H, Bertelsen BE, Gandini S, et al
     Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules.
     J Natl Cancer Inst. 2024;116:1979-1982.
     PubMed     Abstract available
     
     
     
141. ARTESE AL, Zhou X, Tometich DB, Small BJ, et al
     Physical activity and cognition: longitudinal findings from the Thinking and Living with Cancer Study.
     J Natl Cancer Inst. 2024;116:2009-2021.
     PubMed     Abstract available
     
     
     
142. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
     Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
     J Natl Cancer Inst. 2024;116:1904-1913.
     PubMed     Abstract available
     
     
     November 2024
143. GRAFF SL, Tinianov S, Kalinsky K
     "Nailing down" risk and improving outcomes in early-stage breast cancer.
     J Natl Cancer Inst. 2024 Nov 22:djae278. doi: 10.1093.
     PubMed    
     
     
     
144. ROMANOS-NANCLARES A, Willett WC, Rosner B, Stover DG, et al
     Proinflammatory Dietary Pattern and Risk of Total and Subtypes of Breast Cancer Among U.S. Women.
     J Natl Cancer Inst. 2024 Nov 20:djae301. doi: 10.1093.
     PubMed     Abstract available
     
     
     
145. ABOUMRAD M, Joshu C, Visvanathan K
     Impact of major depressive disorder on breast cancer outcomes: a national retrospective cohort study.
     J Natl Cancer Inst. 2024 Nov 12:djae287. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. ROBERTI S, van Leeuwen FE, Diallo I, de Vathaire F, et al
     Prediction of breast cancer risk for adolescents and young adults with Hodgkin lymphoma.
     J Natl Cancer Inst. 2024 Nov 1:djae274. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2024
147. FOSTER VM, Trentham-Dietz A, Stout NK, Lee CI, et al
     Supplemental breast cancer screening after negative mammography in U.S. women with dense breasts.
     J Natl Cancer Inst. 2024 Oct 30:djae272. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. KJAERGAARD KA, Kousholt A, Thomsen RW, Woolpert KM, et al
     Risk of type-2-diabetes after breast cancer treatment: a population-based cohort study in Denmark.
     J Natl Cancer Inst. 2024 Oct 22:djae261. doi: 10.1093.
     PubMed     Abstract available
     
     
     
149. KARLSSON P, Fyles A, Chang SL, Arrick B, et al
     Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
     J Natl Cancer Inst. 2024 Oct 18:djae262. doi: 10.1093.
     PubMed     Abstract available
     
     
     
150. ROMANOS-NANCLARES A, Schernhammer E, Willett WC, Holmes MD, et al
     Consumption of aspartame and risk of breast cancer in the Nurses' Health Studies.
     J Natl Cancer Inst. 2024 Oct 17:djae259. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. SHERMAN ME, Winham SJ, Vierkant RA, Mccauley BM, et al
     Polygenic risk scores stratify breast cancer risk among women with benign breast disease.
     J Natl Cancer Inst. 2024 Oct 16:djae255. doi: 10.1093.
     PubMed     Abstract available
     
     
     
152. JOHN EM, Koo J, Ingles SA, Keegan TH, et al
     Risk factors for second primary breast cancer by laterality, age, and race and ethnicity.
     J Natl Cancer Inst. 2024 Oct 11:djae254. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. WATTS EL, Moore SC, Abar L, Hong HG, et al
     Physical activity, metabolites, and breast cancer associations.
     J Natl Cancer Inst. 2024 Oct 9:djae246. doi: 10.1093.
     PubMed     Abstract available
     
     
     
154. CARROLL JE, Crespi CM, Cole S, Ganz PA, et al
     Transcriptomic markers of biological aging in breast cancer survivors: a longitudinal study.
     J Natl Cancer Inst. 2024 Oct 8:djae201. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2024
155. MARCZYK M, Kahn A, Silber A, Rosenblit M, et al
     Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017.
     J Natl Cancer Inst. 2024 Sep 30:djae241. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. PAGLIUCA M, Havas J, Thomas E, Drouet Y, et al
     Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model.
     J Natl Cancer Inst. 2024 Sep 9:djae222. doi: 10.1093.
     PubMed     Abstract available
     
     
     
157. DAS S, Wentzensen N, Sawaya GF, Egemen D, et al
     Primary human papillomavirus testing vs cotesting: clinical outcomes in populations with different disease prevalence.
     J Natl Cancer Inst. 2024;116:1525-1529.
     PubMed     Abstract available
     
     
     
158. MANDELBLATT J, Dage JL, Zhou X, Small BJ, et al
     Alzheimer disease-related biomarkers and cancer-related cognitive decline: the Thinking and Living with Cancer study.
     J Natl Cancer Inst. 2024;116:1495-1507.
     PubMed     Abstract available
     
     
     August 2024
159. ZHANG Y, Lindstrom S, Kraft P, Liu Y, et al
     Genetic Risk, Health-Associated Lifestyle, and Risk of Early-onset Total Cancer and Breast Cancer.
     J Natl Cancer Inst. 2024 Aug 27:djae208. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. EBRAHIMOGHLI R, Aghaei MH, Azami-Aghdash S, Houssami N, et al
     Uptake of Breast Cancer Screening Practices in Low and Middle-Income Countries: A Systematic Review and Meta-Analysis.
     J Natl Cancer Inst. 2024 Aug 12:djae187. doi: 10.1093.
     PubMed     Abstract available
     
     
     
161. FOLDI J, Carleton N, Anderson SJ, Rastogi P, et al
     Long-term outcomes by lobular versus ductal histology in four NSABP adjuvant breast cancer trials.
     J Natl Cancer Inst. 2024 Aug 10:djae188. doi: 10.1093.
     PubMed     Abstract available
     
     
     
162. MALAGON T
     Time to change the paradigm for primary endpoints in cancer screening trials?
     J Natl Cancer Inst. 2024;116:1187-1189.
     PubMed    
     
     
     July 2024
163. MASSA D, Vernieri C, Nicole L, Criscitiello C, et al
     Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer.
     J Natl Cancer Inst. 2024 Jul 31:djae178. doi: 10.1093.
     PubMed     Abstract available
     
     
     
164. HURSON AN, Ahearn TU, Koka H, Jenkins BD, et al
     Risk factors for breast cancer subtypes by race and ethnicity: A scoping review.
     J Natl Cancer Inst. 2024 Jul 17:djae172. doi: 10.1093.
     PubMed     Abstract available
     
     
     
165. ZHENG G, Baandrup L, Wang J, Hertzum-Larsen R, et al
     Ovarian cancer risk factors in relation to family history.
     J Natl Cancer Inst. 2024 Jul 4:djae164. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2024
166. DENT R, Cortes J, Pusztai L, McArthur H, et al
     Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study.
     J Natl Cancer Inst. 2024 Jun 24:djae129. doi: 10.1093.
     PubMed     Abstract available
     
     
     
167. JAGUST P, Powell AM, Ola M, Watson L, et al
     RET overexpression leads to increased brain metastatic competency in luminal breast cancer.
     J Natl Cancer Inst. 2024 Jun 10:djae091. doi: 10.1093.
     PubMed     Abstract available
     
     
     
168. CHUA AV JR, Sheng H, Liang E, Gandhi S, et al
     Epidemiology of early vs. Late recurrence among women with Early-Stage estrogen Receptor-Positive breast cancer in the pathways study.
     J Natl Cancer Inst. 2024 Jun 6:djae128. doi: 10.1093.
     PubMed     Abstract available
     
     
     
169. LIN J, Ouyang Y, Li Y, Jin L, et al
     Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer.
     J Natl Cancer Inst. 2024 Jun 4:djae115. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2024
170. 
     Correction to: Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy.
     J Natl Cancer Inst. 2024 May 8:djae093. doi: 10.1093.
     PubMed    
     
     
     
171. VO JB, Ramin C, Veiga LHS, Brandt C, et al
     Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in U.S. breast cancer survivors.
     J Natl Cancer Inst. 2024 May 8:djae107. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2024
172. OMOLEYE OJ, Esserman LJ, Olopade OI
     RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
     J Natl Cancer Inst. 2024;116:627-628.
     PubMed    
     
     
     
173. VILLY MC, Le Ven A, Le Mentec M, Masliah-Planchon J, et al
     Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
     J Natl Cancer Inst. 2024;116:580-587.
     PubMed     Abstract available
     
     
     
174. SANDOVAL RL, Bottosso M, Tianyu L, Polidorio N, et al
     TP53-associated early breast cancer: new observations from a large cohort.
     J Natl Cancer Inst. 2024 Apr 3:djae074. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
175. ZENG E, He W, Sjolander A, Bergqvist J, et al
     Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
     J Natl Cancer Inst. 2024 Mar 12:djae061. doi: 10.1093.
     PubMed     Abstract available
     
     
     
176. HUBBARD RA, Su YR, Bowles EJ, Ichikawa L, et al
     Predicting five-year interval second breast cancer risk in women with prior breast cancer.
     J Natl Cancer Inst. 2024 Mar 11:djae063. doi: 10.1093.
     PubMed     Abstract available
     
     
     
177. LEE CI, Elmore JG
     Beyond survival: a closer look at lead-time bias and disease-free intervals in mammography screening.
     J Natl Cancer Inst. 2024;116:343-344.
     PubMed    
     
     
     
178. KUMAR N, Ehsan S, Banerjee S, Fernandez Perez C, et al
     The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis.
     J Natl Cancer Inst. 2024 Mar 5:djae056. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2024
179. LI JL, McClellan JC, Zhang H, Gao G, et al
     Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.
     J Natl Cancer Inst. 2024 Feb 23:djae041. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum